Kendomycin is a polyketide macrolide antibiotic isolated from various Streptomyces strains, with demonstrated cytotoxic and antiosteoporotic properties. Structurally intriguing to synthetic chemists, the macrocycle of Kendomycin contains a rare quinone methide chromophore. The antibiotic activity of Kendomycin shows efficacy against a range of bacteria including Methicillin- and Vancomycin-resistant Staphylococcus aureus. Studies correlate the demonstrated cytotoxicity of Kendomycin against multiple tumor cell lines to an inhibition of chymotrypsin-like proteasome activity. Kendomycin is also described to disable the antiapoptotic protein Bcl-xl by blocking protein-protein interaction with Bak, though this finding showed no direct correlation to cytotoxicity. Early reports described Kendomycin as an endothelin receptor antagonist, and the antiosteoporotic effects were correlated to CT-R (calcitonin receptor) agonism. Kendomycin is an inhibitor of ETAR and ETBR.
1. Yuan, Y., et al. 2004. J. Am. Chem. Soc. 126: 14720-14721. PMID: 15535687
2. Mulzer, J., et al. 2004. Proc. Natl. Acad. Sci. U.S.A. 101: 11980-11985. PMID: 15277689
3. Elnakady, Y.A., et al. 2007. Chembiochem. 8: 1261-1272. PMID: 17592829
4. Janssen, C.O., et al. 2008. Bioorg. Med. Chem. Lett. 18: 5771-5773. PMID: 18845435
5. Bahnck, K.B., et al. 2008. J. Am. Chem. Soc. 130: 13177-13181. PMID: 18767844
6. Martin, H.J., et al. 2010. Angew. Chem. Int. Ed. Engl. 49: 5614-5626. PMID: 20818753